For individuals living with Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a debilitating condition, the arrival of Vyndamax and Tafamidis meglumine represents a significant breakthrough . These novel therapies preserve the transthyretin protein, slowing its damaging build-up and lessening the s